Recent Advances in Preparation and Modification of Gelatin Nanoparticles for Pharmaceutical Applications
DOI:
https://doi.org/10.37285/ijpsn.2018.11.1.2Abstract
Nanoparticles can be produced from the proteinaceous materials called gelatin. Gelatin is extracted from collagen of skin, bones, and connective tissues by controlled acidic or basic hydrolysis. This paper focuses on several methods developed for preparing and modifying gelatin nano-particles (GNPs) for delivery of gene and drugs. In general, eight methods are being used for producing GNPs: the coacervation method; the two step desolvation method; the complex coacervation process; the solvent extraction or emulsion process; the nanoprecipitation method; the microemulsion method; the inverse miniemulsion technique and self-assembly method. The problem of being phagocytosized by the mononuclear phagocyte system (MPS) in the body is among the limitations of native GNPs encounter. The interest was based on the facts that gelatin has been known for its low immunogenicity for many years and is administered intravenously since it is an ingredient of various registered blood substitutes. The advantage offered by the amino acid side-chains of the gelatin matrix molecule is the option of multiple further modifications. Hence, GNPs’ surface modification is typically needed to tackle phagocytosis. Many researchers have reported the gelatin use for anticancer drugs delivery, gene delivery, pulmonary drug delivery, ocular drug delivery and protein delivery.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Keywords:
Collagen, Gelatin nanoparticles, pharmaceutical, Modification, Drug delivery
Downloads
Published
2018-01-31
How to Cite
1.
Gabriel T, Brhane Y. Recent Advances in Preparation and Modification of Gelatin Nanoparticles for Pharmaceutical Applications. Scopus Indexed [Internet]. 2018 Jan. 31 [cited 2024 Dec. 22];11(1):3950-6. Available from: https://ijpsnonline.com/index.php/ijpsn/article/view/347
Issue
Section
Review Articles
References
Azimi B, Nourpanah P, Rabiee M and Arbab S (2014). Producing GNPs as Delivery System for Bovine Serum Albumin. Iranian Biomedical J 18: 34-40.
Babaei Z, Jahanshahi M, and Sanati MH (2008). Fabrication and evaluation of gelatin nanoparticles for delivering of anti - cancer drug. International Journal of Nano science and Nano technology 4(1): 23-30.
Bharti N, Harikumar SL, Shishu, and Buddiraja A (2014). Formulation and evaluation of GNPs for pulmonary drug delivery.World Journal of Pharmacy and Pharmaceutical Sciences 3:733-744.
Breitenbach MA, Kamm W, Hungere KD, Hund H, and Kissel T (1999). Oral and nasal administration of tetanus toxoid loaded nanoparticles consisting of novel charged biodegradable polyesters for mucosal vaccination. Proc. Intern. Symp. Control. Release. Bioact. Mater. 26: 348-349.
Cascone MG, Lazzeri L, Carmignani C, and Zhu Z (2002). GNPs produced by a simple W/O emulsion as delivery system for methotrexate. J Materials Science: Materials in Medicine 13: 523-526.
Coester C, Nayyar P, and Samuel J (2006). In-vitro uptake of GNPs by murine dendritic cells and their intracellular localization. Eur J Pharm Biopharm 62: 306-314.
Coester CJ, Langer K, VonBriesen H, and Kreuter J (2000b). GNPs by two-step desolvation a new preparation method, surface modification and cell uptake. J Microencapsul 17:187-193.
Ethirajan A, Schoeller K, Musyanovych A, Ziener U, and Landfester K (2008). Synthesis and optimization of GNPs using the miniemulsion process. Biomacromolecules 9: 2383-2389.
Fraunhofer W (2003). Asymmetrical Flow Field-Flow-Fractionation in Pharmaceutical Analytics; Investigations in Aggregation Tendencies of Pharmaceutical Antibodies, disseratation, Ludwig-Maximilians-Universität München.p.1-226.
Fuchs S (2010). GNPs as a Modern Platform for Drug Delivery-Formulation; Development and Immunotherapeutic Strategies. PhD dissertation, Ludwig-Maximilians- Universität München. p.1-279. (Accessed 2016 September 2]. Available from: https://edoc.ub.uni-muenchen.de/13692/1/Fuchs_Sebastian.pdf).
Gupta AK, Gupta M, Yarwood SJ and Curtis AS (2004). Effect of cellular uptake of GNPs on adhesion, morphology and cytoskeleton organization of human fibroblasts. J Control Release 95: 197–207.
Jahanshahi M and Babaei Z (2008). Protein nanoparticle: A unique system as drug delivery Vehicles. Afr J Biotech 7: 4926-4934.
Kaintura R, Sharma P, Singh S, Rawat K, and Solanki PR (2015). GNPs as a Delivery System for Proteins. J Nanomed Res 2(1): 00018.
Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, Xie J and Yang Z (2016). Delivery of Nanoparticles for Treatment of Brain Tumor. Curr Drug Metab 17(8): 745-754.
Karthikeyan S, Prasad NR, Ganamani A and Balamurugan E (2013). Anticancer activity of resveratrol-loaded GNPs on NCI-H460 non-small cell lung cancer cells. Biomedicine & Preventive Nutrition 3: 64-73.
Kaul G and Amiji M (2004). Biodistribution and targeting potential of poly (ethylene glycol)-modified GNPs in subcutaneous murine tumor model. J Drug Target 12: 585-591.
Khan SA (2014). GNPs as Potential Nanocarriers for Macromolecular Drugs. Dissertation, Philipps-Universität Marburg. p.1-115.
Khan SA and Schneider M (2013). Improvement of Nanoprecipitation Technique for Preparation of Gelatin Nanoparticles and Potential Macromolecular Drug Loading. Macromolecular Bioscience 13(4): 455-63.
Kim KJ and Byun Y (1999). Preparation and characterizations of self-assembled PEGylated GNPs. Biotechnology and Bioprocess Engineering 4: 210-214.
Kommareddy S, Shenoy DB, and Amiji MM (2005). GNPs and their bio-functionalization. In: Kumar C.S.S.R (Ed.), Nanotechnologies for the Life Sciences, Vol. 1 Bio-functionalization of Nanomaterials, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. p. 330-352.
Kuo W, Huang H, Chou M, Wu M, and Huang Y (2011). Surface Modification of Gelatin Nanoparticles with Polyethylenimine as Gene Vector. J Nanomaterials.
Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, and Schubert D (2003). Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180.
Lee EJ, Khan SA, Park JK, and Lim K (2012). Studies on the characteristics of drug loaded GNPs prepared by nanoprecipitation. Bioprocess Biosyst Eng 35:297-307.
Li WM, Liu DM, and Chen SY (2011). Amphiphilically modified GNPs: self- assembly behavior, controlled biodegradability, and rapid cellular uptake for intracellular drug delivery. J Mater Chem 21: 1238-12388.
Lohcharoenkal W, Wang L, Chen YC, and Rojanasakul Y (2014). Protein nanoparticles as drug delivery carriers for cancer Therapy. BioMed Research International Volume 2014.
Madan J, Dhiman N, Sardana S, Aneja R, Chandra R and Katyal A (2011). Long-circulating poly(ethylene glycol)-grafted GNPs customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 22: 543–555.
Mahapatro A and Singh DK (2011). Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. J Nano-biotechnic 9: 1477-3155-9-55.
Mohanty B, Aswal VK, Kohlbrecher J, and Bohidar HB (2005). Synthesis of GNPs via simple coacervation. J Surf Sci Technol 21: 149-160.
Nahar M, Mishra D, Dubey V, and Jain NK (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded GNPs. Nanomedicine 4: 252–261.
Narayanan D, M GG, H L, Koyakutty M, Nair S, and Menon D (2013). Poly-(ethylene glycol) modified GNPs for sustained Delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis. Nanomedicine 9: 818-828.
Obata Y, Nishino T, Kushibiki T, Tomoshige R, Xia Z, Miyazaki M, et al (2012). HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. Acta Bio materialis 8: 2688-2696.
Rahimnejad M, Mokhtarian N, and Ghasemi M (2009). Production of protein nanoparticles for food and drug delivery system. Afr J Biotech 8: 4738-4743.
Santoro M, Tatara AM, and Mikos AG (2014). Gelatin carriers for drug and cell delivery in tissue engineering. J Controlled Release 190: 210-218.
Sun Y, Kang C, Liu F, and Song L (2016). Delivery of Antipsychotics with Nanoparticles. Drug Development Research 77(7): 393-399.
Sussman EM, Clarke MB, and Shastri VP (2007). Single-step process to produce surface-functionalized polymeric nanoparticles. Langmuir 23: 12275-12279.
Tanigo T, Takaoka R, and Tabata Y (2010). Sustained release of water-insoluble simvastatin from biodegradable hydrogel augments bone regeneration. J Control Release 143: 201-206.
Tseng CL, Su WY, Yen KC, Yang C, and Lin FH (2009). The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation incancerous lungs via inhalation. Biomaterials 30: 3476-3485.
Vandervoort J and Ludwig A (2004). Preparation and evaluation of drug-loaded gelatin for topical ophthalmic use. Eur J Pharm Biopharm 57: 251-261.
Wang G, Siggers K, Zhang S, Jiang H, Xu Z, Zernicke RF, et al (2008). Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 25: 2896-2909.
Wang H, Boerman OC, Sariibrahimoglu K, Li Y, Jansen JA, and Leeuwenburgh SC (2012). Comparison of micro- vs. nanostructured colloidal gelatin gels for sustained delivery of osteogenic proteins: Bone morphogenetic protein-2 and alkaline phosphatase. Biomaterials 33: 8695-8703.
Xu X, Capito RM, and Spector M (2008). Delivery of plasmid IGF-1 to chondrocytes via cationized GNPs. J Biomed Mater Res 84: 73-83.
Young S, Wong M, Tabata Y, and Mikos AG (2005). Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Controlled Release 109: 256-274.
Zhai X (2013). GNPs & nanocrystals for dermal delivery. Inaugural Dissertation. Universität Berlin. p.1-142. (Accessed 2016 August 18].
Zhao YZ, Li X, Lu CT, Xu YY, Lv HF, Dai DD, et al (2012). Experiment on the feasibility of using modified GNPs as insulin pulmonary administration system for diabetes therapy. Acta Diabetol 49: 315-325.
Zillies, JC (2007). GNPs for Targeted Oligonucleotide Delivery to Kupffer Cells-Analytics, Formulation Development, Practical Application, in Department of Pharmacy: Pharmaceutical Technology and Biopharmaceutics. Ph.D dissertation, Ludwig-Maximilians-Universität München.p.1-251.
Zwiorek K (2006). GNPs as Delivery System for Nucleotide-Based Drugs, in department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics. Ph.D dissertation.p.1-226.
Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, et al (2008). Delivery by cationic GNPs strongly increases the immuno stimulatory effects of CpG oligonucleotides. Pharm Res 25: 551-562.
Zwiorek K, Kloeckner J, Wagner E and Coester C (2004). Gelatin nanoparticles as a new and simple gene delivery system. J Pharm PharmaceutSci 7(4): 22-28.
Babaei Z, Jahanshahi M, and Sanati MH (2008). Fabrication and evaluation of gelatin nanoparticles for delivering of anti - cancer drug. International Journal of Nano science and Nano technology 4(1): 23-30.
Bharti N, Harikumar SL, Shishu, and Buddiraja A (2014). Formulation and evaluation of GNPs for pulmonary drug delivery.World Journal of Pharmacy and Pharmaceutical Sciences 3:733-744.
Breitenbach MA, Kamm W, Hungere KD, Hund H, and Kissel T (1999). Oral and nasal administration of tetanus toxoid loaded nanoparticles consisting of novel charged biodegradable polyesters for mucosal vaccination. Proc. Intern. Symp. Control. Release. Bioact. Mater. 26: 348-349.
Cascone MG, Lazzeri L, Carmignani C, and Zhu Z (2002). GNPs produced by a simple W/O emulsion as delivery system for methotrexate. J Materials Science: Materials in Medicine 13: 523-526.
Coester C, Nayyar P, and Samuel J (2006). In-vitro uptake of GNPs by murine dendritic cells and their intracellular localization. Eur J Pharm Biopharm 62: 306-314.
Coester CJ, Langer K, VonBriesen H, and Kreuter J (2000b). GNPs by two-step desolvation a new preparation method, surface modification and cell uptake. J Microencapsul 17:187-193.
Ethirajan A, Schoeller K, Musyanovych A, Ziener U, and Landfester K (2008). Synthesis and optimization of GNPs using the miniemulsion process. Biomacromolecules 9: 2383-2389.
Fraunhofer W (2003). Asymmetrical Flow Field-Flow-Fractionation in Pharmaceutical Analytics; Investigations in Aggregation Tendencies of Pharmaceutical Antibodies, disseratation, Ludwig-Maximilians-Universität München.p.1-226.
Fuchs S (2010). GNPs as a Modern Platform for Drug Delivery-Formulation; Development and Immunotherapeutic Strategies. PhD dissertation, Ludwig-Maximilians- Universität München. p.1-279. (Accessed 2016 September 2]. Available from: https://edoc.ub.uni-muenchen.de/13692/1/Fuchs_Sebastian.pdf).
Gupta AK, Gupta M, Yarwood SJ and Curtis AS (2004). Effect of cellular uptake of GNPs on adhesion, morphology and cytoskeleton organization of human fibroblasts. J Control Release 95: 197–207.
Jahanshahi M and Babaei Z (2008). Protein nanoparticle: A unique system as drug delivery Vehicles. Afr J Biotech 7: 4926-4934.
Kaintura R, Sharma P, Singh S, Rawat K, and Solanki PR (2015). GNPs as a Delivery System for Proteins. J Nanomed Res 2(1): 00018.
Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, Xie J and Yang Z (2016). Delivery of Nanoparticles for Treatment of Brain Tumor. Curr Drug Metab 17(8): 745-754.
Karthikeyan S, Prasad NR, Ganamani A and Balamurugan E (2013). Anticancer activity of resveratrol-loaded GNPs on NCI-H460 non-small cell lung cancer cells. Biomedicine & Preventive Nutrition 3: 64-73.
Kaul G and Amiji M (2004). Biodistribution and targeting potential of poly (ethylene glycol)-modified GNPs in subcutaneous murine tumor model. J Drug Target 12: 585-591.
Khan SA (2014). GNPs as Potential Nanocarriers for Macromolecular Drugs. Dissertation, Philipps-Universität Marburg. p.1-115.
Khan SA and Schneider M (2013). Improvement of Nanoprecipitation Technique for Preparation of Gelatin Nanoparticles and Potential Macromolecular Drug Loading. Macromolecular Bioscience 13(4): 455-63.
Kim KJ and Byun Y (1999). Preparation and characterizations of self-assembled PEGylated GNPs. Biotechnology and Bioprocess Engineering 4: 210-214.
Kommareddy S, Shenoy DB, and Amiji MM (2005). GNPs and their bio-functionalization. In: Kumar C.S.S.R (Ed.), Nanotechnologies for the Life Sciences, Vol. 1 Bio-functionalization of Nanomaterials, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. p. 330-352.
Kuo W, Huang H, Chou M, Wu M, and Huang Y (2011). Surface Modification of Gelatin Nanoparticles with Polyethylenimine as Gene Vector. J Nanomaterials.
Langer K, Balthasar S, Vogel V, Dinauer N, Von Briesen H, and Schubert D (2003). Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180.
Lee EJ, Khan SA, Park JK, and Lim K (2012). Studies on the characteristics of drug loaded GNPs prepared by nanoprecipitation. Bioprocess Biosyst Eng 35:297-307.
Li WM, Liu DM, and Chen SY (2011). Amphiphilically modified GNPs: self- assembly behavior, controlled biodegradability, and rapid cellular uptake for intracellular drug delivery. J Mater Chem 21: 1238-12388.
Lohcharoenkal W, Wang L, Chen YC, and Rojanasakul Y (2014). Protein nanoparticles as drug delivery carriers for cancer Therapy. BioMed Research International Volume 2014.
Madan J, Dhiman N, Sardana S, Aneja R, Chandra R and Katyal A (2011). Long-circulating poly(ethylene glycol)-grafted GNPs customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 22: 543–555.
Mahapatro A and Singh DK (2011). Biodegradable nanoparticles are excellent vehicle for site directed in vivo delivery of drugs and vaccines. J Nano-biotechnic 9: 1477-3155-9-55.
Mohanty B, Aswal VK, Kohlbrecher J, and Bohidar HB (2005). Synthesis of GNPs via simple coacervation. J Surf Sci Technol 21: 149-160.
Nahar M, Mishra D, Dubey V, and Jain NK (2008). Development, characterization, and toxicity evaluation of amphotericin B-loaded GNPs. Nanomedicine 4: 252–261.
Narayanan D, M GG, H L, Koyakutty M, Nair S, and Menon D (2013). Poly-(ethylene glycol) modified GNPs for sustained Delivery of the anti-inflammatory drug Ibuprofen-Sodium: An in vitro and in vivo analysis. Nanomedicine 9: 818-828.
Obata Y, Nishino T, Kushibiki T, Tomoshige R, Xia Z, Miyazaki M, et al (2012). HSP47 siRNA conjugated with cationized gelatin microspheres suppresses peritoneal fibrosis in mice. Acta Bio materialis 8: 2688-2696.
Rahimnejad M, Mokhtarian N, and Ghasemi M (2009). Production of protein nanoparticles for food and drug delivery system. Afr J Biotech 8: 4738-4743.
Santoro M, Tatara AM, and Mikos AG (2014). Gelatin carriers for drug and cell delivery in tissue engineering. J Controlled Release 190: 210-218.
Sun Y, Kang C, Liu F, and Song L (2016). Delivery of Antipsychotics with Nanoparticles. Drug Development Research 77(7): 393-399.
Sussman EM, Clarke MB, and Shastri VP (2007). Single-step process to produce surface-functionalized polymeric nanoparticles. Langmuir 23: 12275-12279.
Tanigo T, Takaoka R, and Tabata Y (2010). Sustained release of water-insoluble simvastatin from biodegradable hydrogel augments bone regeneration. J Control Release 143: 201-206.
Tseng CL, Su WY, Yen KC, Yang C, and Lin FH (2009). The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation incancerous lungs via inhalation. Biomaterials 30: 3476-3485.
Vandervoort J and Ludwig A (2004). Preparation and evaluation of drug-loaded gelatin for topical ophthalmic use. Eur J Pharm Biopharm 57: 251-261.
Wang G, Siggers K, Zhang S, Jiang H, Xu Z, Zernicke RF, et al (2008). Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 25: 2896-2909.
Wang H, Boerman OC, Sariibrahimoglu K, Li Y, Jansen JA, and Leeuwenburgh SC (2012). Comparison of micro- vs. nanostructured colloidal gelatin gels for sustained delivery of osteogenic proteins: Bone morphogenetic protein-2 and alkaline phosphatase. Biomaterials 33: 8695-8703.
Xu X, Capito RM, and Spector M (2008). Delivery of plasmid IGF-1 to chondrocytes via cationized GNPs. J Biomed Mater Res 84: 73-83.
Young S, Wong M, Tabata Y, and Mikos AG (2005). Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J Controlled Release 109: 256-274.
Zhai X (2013). GNPs & nanocrystals for dermal delivery. Inaugural Dissertation. Universität Berlin. p.1-142. (Accessed 2016 August 18].
Zhao YZ, Li X, Lu CT, Xu YY, Lv HF, Dai DD, et al (2012). Experiment on the feasibility of using modified GNPs as insulin pulmonary administration system for diabetes therapy. Acta Diabetol 49: 315-325.
Zillies, JC (2007). GNPs for Targeted Oligonucleotide Delivery to Kupffer Cells-Analytics, Formulation Development, Practical Application, in Department of Pharmacy: Pharmaceutical Technology and Biopharmaceutics. Ph.D dissertation, Ludwig-Maximilians-Universität München.p.1-251.
Zwiorek K (2006). GNPs as Delivery System for Nucleotide-Based Drugs, in department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics. Ph.D dissertation.p.1-226.
Zwiorek K, Bourquin C, Battiany J, Winter G, Endres S, Hartmann G, et al (2008). Delivery by cationic GNPs strongly increases the immuno stimulatory effects of CpG oligonucleotides. Pharm Res 25: 551-562.
Zwiorek K, Kloeckner J, Wagner E and Coester C (2004). Gelatin nanoparticles as a new and simple gene delivery system. J Pharm PharmaceutSci 7(4): 22-28.
